Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation

According to the results of a recent database study, among patients with DLBCL who did not receive second-line stem cell transplantation, most healthcare resource utilization and DLBCL-related claims costs were due to hospitalizations and outpatient visits. Most patients received second-line rituximab (39.5%) or bendamustine ± rituximab ± other (16.3%), and over half were hospitalized (mean duration: 16.5 [SD: 25.8] days per patient per year [PPPY]). Mean medical/pharmacy costs were US$141,532 PPPY (SD: $189,579).